Investigational Products: Niraparib Period: 3 years after IRB/EC approval Indication: Adult patients with histologically confirmed and locally advanced, unresectable, or metastatic solid tumors having known or suspected deleterious mutations in genes involved in homologous recombination repair (HRR) or homologous recombination deficiency identified by whole genome sequencing
Patient who agreed to participate in the KOSMOS-II master observation study.
19 years of age or older on the day of signing informed consent.
Has a histologically- or cytologically-confirmed advanced (metastatic and/or unresectable) solid tumor.
Has either known or suspected deleterious mutations in at least 1 of the genes involved in HRR or centrally confirmed HRD based on whole-genome sequencing (WGS).
Any previous exposure to PARP inhibitor
Any other active malignancy or diagnosis of another malignancy within 2 years before study enrollment
Has leptomeningeal metastases.
Active central nervous system (CNS) lesions.
Single group
Niraparib
Druga highly selective PARP1 and PARP2 inhibitor
objective response after 8 weeks
Antitumor activity defined as objective response after 8 weeks
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
